Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis
- PMID: 16614977
- DOI: 10.1007/s10620-006-3180-5
Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis
Abstract
In primary sclerosing cholangitis (PSC), biliary enrichment of ursodeoxycholic acid (UDCA) may represent the decisive factor for its presumable beneficial effect. Up to now it is not clear how colitis and colectomy with ileo-anal pouch affect the biliary enrichment of UDCA and the biliary bile acid composition. We determined the biliary bile acid composition in 63 patients with PSC including 7 patients with ileo-anal pouch, 31 patients with colitis, and 25 patients without colitis. No differences existed between patients with and those without colitis. In patients with colectomy and pouch at a UDCA dose of 17.7 +/- 1.6 mg/kg (n = 7), biliary UDCA represented 46.4 +/- 6.7% (mean +/- SD) of total bile acids. An increase in the dose in six pouch patients from 12.5 +/- 0.9 to 22.3 +/- 1.6 mg/kg led to a slight increase in biliary enrichment of UDCA, from 39.8 +/- 8.1 to 49.4 +/- 10.7%. In five of seven patients with ileo-anal pouch, biliary UDCA enrichment was within the normal range, and in two of seven it was permanently or intermittently abnormally low. During UDCA treatment, in pouch patients the biliary content of deoxycholic acid and lithocholic acid was reduced, whereas all other bile acids were unchanged. In a minority of patients with ileo-anal pouch, biliary enrichment of UDCA may be markedly reduced, whereas patients with colitis have a biliary UDCA enrichment not different from that of patient without colitis.
Similar articles
-
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.Hepatology. 2010 Jul;52(1):197-203. doi: 10.1002/hep.23631. Hepatology. 2010. PMID: 20564380 Free PMC article.
-
Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.Hepatology. 2004 Sep;40(3):693-8. doi: 10.1002/hep.20370. Hepatology. 2004. PMID: 15349909
-
Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.J Hepatol. 1996 Dec;25(6):887-94. doi: 10.1016/s0168-8278(96)80293-5. J Hepatol. 1996. PMID: 9007717 Clinical Trial.
-
Primary sclerosing cholangitis.Can J Gastroenterol. 2000 Apr;14(4):311-5. doi: 10.1155/2000/983681. Can J Gastroenterol. 2000. PMID: 10799084 Review.
-
[Treatment of cholestatic liver diseases with ursodeoxycholic acid].Tidsskr Nor Laegeforen. 1997 Sep 30;117(23):3370-3. Tidsskr Nor Laegeforen. 1997. PMID: 9411890 Review. Norwegian.
Cited by
-
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.Hepatology. 2010 Jul;52(1):197-203. doi: 10.1002/hep.23631. Hepatology. 2010. PMID: 20564380 Free PMC article.
-
Treatment of primary sclerosing cholangitis.Curr Treat Options Gastroenterol. 2007 Apr;10(2):111-9. doi: 10.1007/s11938-007-0063-6. Curr Treat Options Gastroenterol. 2007. PMID: 17391626
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources